Singulex, Inc.’s Proprietary Ultrasensitive Research Test For Cardiac Troponin-I Predicts Coronary Heart Disease In The General Population

ALAMEDA, Calif.--(BUSINESS WIRE)--Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, yesterday presented new data at the American Heart Association Epidemiology and Prevention Council Conference highlighting research results using the Company’s proprietary ultrasensitive Erenna® Immunoassay System in the detection of cardiac troponin-I (cTnI). The study utilized the Erenna System to measure previously undetected increases in cTnI to predict development of coronary heart disease (CHD) in the general population, independent of a variety of traditional risk factors.

Help employers find you! Check out all the jobs and post your resume.